Cite
HARVARD Citation
Ostenfeld, T. et al. (n.d.). [O2–09–02]: EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA‐AMYLOID 42 (Aβ42)‐SPECIFIC ANTIBODY, IN PATIENTS WITH MILD‐MODERATE ALZHEIMER'S DISEASE. Alzheimer's & dementia. p. P574. [Online].